All In Biotech

Drug Trial Radar · NCT07230834

Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

A Phase 1 Dose-Escalation and Repeated-Dose Study of the Safety and Tolerability of Intravitreal Pozelimab in Participants With Geographic Atrophy

Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Jan 19, 2026

Primary completion

Jul 3, 2028

Study completion Jul 3, 2028

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Nov 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, which can make it harder to see. This is called geographic atrophy (GA). The aim of the study is to see how safe and tolerable the study drug is when used as an injection in the eye. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood and the fluid in the eye at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Conditions

  • Geographic Atrophy (GA)

Interventions

  • PozelimabDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of ocular Treatment-Emergent Adverse Event (TEAEs) in the study eyeTime frame: Through week 8
  2. Occurrence of ocular TEAEs in the study eyeTime frame: Through week 16
  3. Occurrence of systemic TEAEsTime frame: Through week 8
  4. Occurrence of systemic TEAEsTime frame: Through week 16

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • Colorado Retina Associates

    Lakewood, Colorado · Recruiting

  • Ophthalmic Consultants of Boston

    East Weymouth, Massachusetts · Recruiting

  • Austin Retina Associates

    Austin, Texas · Recruiting

  • Retina Foundation of the Southwest

    Dallas, Texas · Recruiting

  • Retina Consultants Texas

    The Woodlands, Texas · Recruiting

  • Arensia Exploratory Medicine at the Research Institute of Clinical Medicine

    Tbilisi, Georgia · Recruiting

  • Emanuelli Research and Development Center

    Arecibo, Puerto Rico · Recruiting

  • ARENSIA Clinics SRL

    Bucharest, Romania · Recruiting

  • Arensia Exploratory Medicine Clinic at Country Hospital Cluj-Napoca

    Cluj-Napoca, Romania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.